Health2Sync
Health2Sync is a Taiwan-founded digital chronic disease management company that operates a patient app and a Patient Management Platform for healthcare providers, serving 1M+ registered users and 280+ medical institutions across Asia-Pacific through subscriptions, enterprise licensing, and pharma/device partnerships.
- Company typePublic
- Founded2013
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What Health2Sync does
Health2Sync (legal entity H2, Inc., incorporated in the Cayman Islands with a Taiwan branch) is a digital chronic disease management company founded in June 2013 in Taiwan. It operates a two-product platform: a consumer-facing Health2Sync App that enables patients to log blood glucose, blood pressure, weight, CGM data, medication, diet, and exercise, with visualization, PDF/Excel reports, and social partner sharing; and a web-based Patient Management Platform that lets clinics, hospitals, and diabetes educators remotely monitor patient data, prioritize cases, and communicate through messaging and goal-setting. The platform integrates with 20+ blood glucose meter brands, Abbott FreeStyle Libre CGM, Novo Nordisk NovoPen 6/Echo Plus, BIOCORP Mallya smart caps, Sanofi SoloSmart, Fitbit, Google Health Connect, Apple Health, and Taiwan's NHI My Health Bank.
The company monetizes through a freemium consumer subscription (Premium at US$3.99/month, US$20.99/6 months, US$36.99/12 months), enterprise licensing of the Patient Management Platform to healthcare institutions (280+ globally), and B2B digital-care partnerships with pharmaceutical companies (Sanofi, Novo Nordisk, AstraZeneca), medical device manufacturers, and government health bodies (Taiwan NHI Administration, Singapore Health Promotion Board). It has documented an average 2.0% HbA1c reduction over three months for users with baseline HbA1c > 7%. The company operates across Taiwan, Japan (subsidiary since 2018), South Korea (SugarGenie sub-brand, 100+ institutions by Dec 2024), Singapore, Malaysia, Australia, Hong Kong, and the Middle East, and runs regulated products including Insultrate (the first basal insulin titration SaMD approved in Taiwan) and SugarGenie. Total disclosed funding exceeds US$30 million, including a US$20 million Series C in March 2025 led by Taiwania Capital, and the company completed its IPO on the Taiwan Emerging Stock Market (TPEx) under stock symbol 7851 in November 2025.
Health2Sync firmographics
Firmographics- Name
- Health2Sync
- Legal name
- H2, Inc.
- Website
- https://health2sync.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Short description
- Health2Sync is a Taiwan-founded digital chronic disease management company that operates a patient app and a Patient Management Platform for healthcare providers, serving 1M+ registered users and 280+ medical institutions across Asia-Pacific through subscriptions, enterprise licensing, and pharma/device partnerships.
- Ownership category
- akta.pro rank
Health2Sync industry classification
Industry- Product category
- Digital Chronic Disease Management Software
- NAICS
- All Other Outpatient Care Centers (621498), Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
- SIC
- Services-Health Services (8000), Services-Prepackaged Software (7372), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension) (HLACAPAD)
- akta.pro secondary industries
- Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
Keywords
Where Health2Sync is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Health2Sync business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Premium Membership Subscription: App-based freemium model with premium tier offering deeper analyses, educational content, unlimited PDF reports, and chatbot support. Basic membership free with limited features.
- Patient Management Platform Enterprise License: B2B platform sold to healthcare institutions (hospitals, clinics) for managing chronic disease patients. Platform enables patient monitoring, communication, and data analytics.
- B2B Digital Care Ecosystem Partnerships: Revenue from partnerships with pharmaceutical companies (Sanofi, Novo Nordisk), medical device manufacturers, and health ministries for population health management solutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Basic Membership - Free tier with core features |
| Subscription | Monthly | Premium Membership - Full access to analyses and reports |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Health2Sync product offering
Product offeringCore offering
Health2Sync operates a digital chronic disease management platform centered on a patient-facing mobile app (Health2Sync App) and a provider-facing web platform (Patient Management Platform). The patient app lets users log and visualize blood glucose, blood pressure, weight, CGM, diet, exercise, and medication, with AI food recognition, chatbot analysis, voice logging, lab report scanning, partner sharing, and PDF reports. The provider platform consolidates patient data for remote monitoring, case prioritization, secure messaging, and analytics, and is used by 280+ medical institutions globally.
Product overview
Health2Sync offers a digital chronic disease management platform centered on two complementary products: the Health2Sync App for patients and the Patient Management Platform for healthcare providers. The patient app enables individuals to record and track blood glucose, blood pressure, weight, CGM data, diet, exercise, and medication with visualization tools, AI-powered food recognition and chatbot analysis, and social care features via the Partners function. The provider platform syncs patient data for remote monitoring, prioritization, and communication. These core products are supplemented by Premium Membership (subscription add-on with deeper analytics), Insultrate (FDA-approved insulin titration SaMD), and the SugarGenie sub-brand deployed in South Korea. The platform integrates with over 50 device brands, CGM systems, insulin pens, and health apps including Fitbit, Google Health Connect, and Apple Health. The company holds ISO 27001:2022 and ISO 27017:2015 certifications for information security.
Differentiator
Problem solved
Functional benefit
Brands
- SugarGenie: Digital disease management app focused on diabetes, hypertension, and obesity care, particularly popular in South Korea.
- Insultrate
- DigiCoach
Products and services
- Health2Sync App Mobile application for patients to log and visualize blood glucose, blood pressure, weight, CGM readings, diet, exercise, and medication; includes AI food recognition, chatbot analysis, voice logging, lab report scanning, partner sharing, and PDF/Excel report generation.
- Patient Management Platform Web-based platform for healthcare providers (clinics, hospitals, diabetes educators) to consolidate patient data, prioritize care cases, communicate securely, set goals, and run remote patient monitoring for diabetes, hypertension, and obesity.
- Smart Cable Hardware cable device that syncs blood glucose data from compatible blood glucose meters to the Health2Sync App via wired connection; sold under Terms of Sale with a 12-month limited warranty.
- Insultrate Insulin self-titration Software-as-a-Medical Device (SaMD) that provides basal insulin titration guidance; first such SaMD approved by Taiwan's FDA.
- SugarGenie Sub-branded digital disease management app focused on diabetes, hypertension, and obesity care, deployed in South Korea with integrated EMR and pharmaceutical partner support.
- DigiCoach CGM-based diabetes prevention program co-developed with Singapore's Health Promotion Board, designed to help at-risk populations prevent diabetes through continuous monitoring and coaching.
Quantifiable outcome
- 2.0% average HbA1c reduction after 3 months of use for users with initial HbA1c > 7%
- +3 more outcomes
Companies that use Health2Sync
Customer profileNamed customers16 records
Segments5 records
Ideal customer profiles4 records
Health2Sync technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
AI capability6 records
Feature4 records
Health2Sync partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Novo NordiskcorePartnership for Mallya smart cap integration with FlexTouch insulin pens in Japan (2023) and South Korea (2025). Also partnered for digital health management promotion in Japan and app integration with NovoPen 6 and NovoPen Echo Plus.
- SanoficoreExtended partnership for digital insulin management solution development. Deployment of Digital Insulin Management Program to 300 clinics in Taiwan over 3 years (2020). Strategic partnership for SoloSmart and SugarGenie promotion in South Korea (2024). Insultrate SaMD certification support.
- AbbottcoreIntegration with FreeStyle LibreLink App for CGM data syncing in Taiwan, Hong Kong, Singapore (2022) and Japan (2021) - first of its kind in Asia.
- BIOCORPcorePartnership to deliver Mallya technology - smart cap for insulin pens enabling digital insulin tracking.
- AstraZenecaminorCollaboration to start digital support program for early CKD (chronic kidney disease) detection in Taiwan (2022).
- Health Promotion Board (Singapore)coreCo-developed DigiCoach - a CGM-based program to prevent diabetes in Singapore (2024).
- Western Sydney DiabetesminorCollaboration to streamline patient care workflow using Health2Sync solution (2024).
- HitachiminorNationwide corporate health insurance ('Kenpo') partnership renewed in Japan (December 2025).
- NTTminorNationwide corporate health insurance ('Kenpo') partnership renewed in Japan (December 2025).
- Taiwan National Health Insurance AdministrationcoreSelected to participate in 'Digital Care Reimbursement Project' (October 2024). Integration with National Health Insurance Taiwan's My Health Bank (2020).
Scale indicators8 records
Recent moves7 records
Expansion highlights7 records
Health2Sync competitors and assessment
Company assessmentBroad incumbents
- Livongo (Teladoc Health): Teladoc's chronic care arm, originally Livongo, offers a diabetes and chronic condition management platform with connected devices, coaching, and provider dashboards — directly analogous to Health2Sync's app + Patient Management Platform stack, though at greater scale and in the US market.
Direct peers
- DarioHealth: Digital chronic condition platform offering a smartphone-connected glucose meter, app-based coaching, and B2B contracts with employers and payers — directly comparable in B2C device + app + B2B SaaS model.
- Vida Health: Digital chronic condition platform covering diabetes, hypertension, and weight management with coaching, app, and employer/payer contracts — directly comparable chronic-condition scope and enterprise GTM.
- One Drop: Consumer diabetes and chronic-condition app with coaching, connected meter, and B2B contracts with insurers and employers — closely comparable freemium-to-premium consumer motion and chronic-condition scope.
- Omada Health: Digital chronic disease prevention and management platform covering diabetes, hypertension, and obesity with employer and payer contracting and connected device support — directly comparable to Health2Sync's PMP enterprise motion and chronic-condition scope.
- Glooko: Diabetes data management platform that aggregates data from 95+ devices and serves both patients and clinicians with population health analytics — directly analogous to Health2Sync's device-agnostic Patient Management Platform approach.
- mySugr (Roche): Acquired by Roche, mySugr is a consumer diabetes app with logging, bolus calculator, and Roche Accu-Chek meter integration, paired with clinician reporting — the closest direct competitor to Health2Sync's app + provider dashboard offering in the diabetes self-management category.
Emerging players
- Noom: Digital weight management and chronic-condition platform with consumer subscription and enterprise contracts; Health2Sync's planned GLP-1-linked weight program (Series C use of funds) targets this adjacent category.
- WellDoc: Developer of FDA-cleared digital therapeutic software (BlueStar) for diabetes management prescribed by physicians — comparable SaMD + chronic disease positioning to Health2Sync's Insultrate, though focused on the US market.
Others
- Abbott FreeStyle Libre (consumer app): Owns the FreeStyle LibreLink App ecosystem that integrates with Health2Sync; represents both a key integration partner and a potential competitor if Abbott deepens its own patient engagement and clinician dashboard features.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Health2Sync social profiles
Digital presenceHealth2Sync compliance and trust
Trust signalCompliance3 records
Health2Sync financial estimates
Financial estimateRevenue estimate
Valuation estimate
Health2Sync leadership team
Management profileNumber of profiles
Profiles2 records
Health2Sync subsidiaries and ownership
Company hierarchySubsidiaries1 record
Health2Sync funding detail
Funding detailFunding overview
Funding rounds7 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Health2Sync M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Health2Sync
What does Health2Sync do?
Health2Sync operates a digital chronic disease management platform centered on a patient-facing mobile app (Health2Sync App) and a provider-facing web platform (Patient Management Platform). The patient app lets users log and visualize blood glucose, blood pressure, weight, CGM, diet, exercise, and medication, with AI food recognition, chatbot analysis, voice logging, lab report scanning, partner sharing, and PDF reports. The provider platform consolidates patient data for remote monitoring, case prioritization, secure messaging, and analytics, and is used by 280+ medical institutions globally.
Is Health2Sync a public or private company?
Health2Sync is a public company. It is classified as public and is currently ipo.
When was Health2Sync founded?
Health2Sync was founded in 2013. It employs 11 to 50 people.
Where is Health2Sync based?
Health2Sync is headquartered in Tokyo, Japan, in the Asia region.
How does Health2Sync make money?
Three revenue lines are on record. Premium Membership Subscription is the primary driver. The others are patient Management Platform Enterprise License and B2B Digital Care Ecosystem Partnerships.
Who are Health2Sync's main competitors?
Livongo (Teladoc Health) is listed as a broad incumbent. Direct peers are DarioHealth, Vida Health, One Drop, Omada Health, Glooko and mySugr (Roche). Emerging players are Noom and WellDoc. Abbott FreeStyle Libre (consumer app) is listed as an others.
Does Health2Sync have an API?
No public API is recorded for Health2Sync.
What industry is Health2Sync in?
Health2Sync's product category is Digital Chronic Disease Management Software. Its primary akta.pro industry code is HLACAPAD, Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension), with a secondary code of HLALADAD, Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN). Its NAICS code is 621498 and its SIC code is 8000.